NCT05672524 2026-03-04
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
61 trialsNCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT03365882 2026-02-10
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT06109467 2026-02-09
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05062889 2026-02-03
ERASE-CRC
Gruppo Oncologico del Nord-Ovest
Phase 2 Suspended
NCT04661150 2026-01-30
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06123338 2026-01-29
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06468280 2026-01-21
ROSETTE
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05515796 2025-08-24
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT06178445 2025-08-19
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT02205047 2025-07-31
INNOVATION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02678182 2025-06-10
PLATFORM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT06589830 2025-05-15
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Suzhou Teligene Ltd.
Phase 2 Not yet recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT03043313 2024-11-26
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Seagen Inc.
Phase 2 Completed
NCT05356897 2024-09-19
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT06439550 2024-06-03
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT04908813 2024-04-15
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
Shanghai Henlius Biotech
Phase 2 Active not recruiting
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05997524 2023-08-18
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT04510285 2023-02-01
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02725424 2022-08-17
MATCH
ChineseAMS
Phase 2 Completed
NCT05170256 2022-08-12
HERES
Rigshospitalet, Denmark
Phase 2 Unknown
NCT05218148 2022-04-06
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
ChineseAMS
Phase 2 Unknown
NCT05311189 2022-04-05
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NCT05193292 2022-01-14
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT04380012 2021-07-15
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04960943 2021-07-14
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Fudan University
Phase 2 Unknown
NCT01359397 2021-01-27
B-DOCT
The Netherlands Cancer Institute
Phase 2 Unknown
NCT03613168 2021-01-05
BILHER
Asan Medical Center
Phase 2 Completed
NCT01402401 2020-12-10
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Novartis
Phase 2 Terminated
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT00515411 2019-12-10
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03766607 2019-09-19
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Korean South West Oncology Group
Phase 2 Withdrawn
NCT00478140 2019-08-20
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03185988 2019-07-19
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Peking University
Phase 2 Unknown
NCT03225937 2018-10-30
HERACLES
Fondazione del Piemonte per l'Oncologia
Phase 2 Unknown
NCT01461057 2018-08-09
JOSHUA
Hoffmann-La Roche
Phase 2 Completed
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed